MANGOCEUTICALS, INC. Files 8-K on Financials

Ticker: MGRX · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1938046

Mangoceuticals, INC. 8-K Filing Summary
FieldDetail
CompanyMangoceuticals, INC. (MGRX)
Form Type8-K
Filed DateAug 15, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: financial-reporting, 8-k

TL;DR

MANGOCEUTICALS, INC. dropped an 8-K detailing financial results and condition.

AI Summary

On August 14, 2024, MANGOCEUTICALS, INC. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or operational details were provided in the excerpt.

Why It Matters

This 8-K filing indicates that MANGOCEUTICALS, INC. is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor the company's health.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial information and does not indicate any immediate or significant risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for MANGOCEUTICALS, INC.?

The primary purpose of this 8-K filing is to report on the company's Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.

On what date was the earliest event reported in this filing?

The earliest event reported in this filing was on August 14, 2024.

In which state is MANGOCEUTICALS, INC. incorporated?

MANGOCEUTICALS, INC. is incorporated in Texas.

What is the SEC file number for MANGOCEUTICALS, INC.?

The SEC file number for MANGOCEUTICALS, INC. is 001-41615.

What is the business address of MANGOCEUTICALS, INC.?

The business address of MANGOCEUTICALS, INC. is 15110 N. Dallas Parkway, Suite 600, Dallas, Texas 75248.

Filing Stats: 932 words · 4 min read · ~3 pages · Grade level 12.2 · Accepted 2024-08-15 09:25:09

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MANGOCEUTICALS, INC. Date: August 15, 2024 By: /s/ Jacob D. Cohen Jacob D. Cohen Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing